Key player · Company profile
Reckitt Benckiser Group PLC
Named as a key player in 198 of our reports, across 33 regions and countries.
Named as a key player in 198 of our reports, across 33 regions and countries.
2023–2033 CAGR · estimates
Australia 6
Brazil 6
Canada 6
China 6
Ecuador 6
Egypt 6
France 6
Germany 6
Hong Kong 6
India 6
Italy 6
Japan 6
Kenya 6
Malaysia 6
Mexico 6
New Zealand 6
Philippines 6
Russia 6
Saudi Arabia 6
Singapore 6
South Africa 6
Spain 6
Thailand 6
UAE 6
UK 6
US 6| Market | Category | World 2023 | CAGR |
|---|---|---|---|
| Over The Counter (OTC) Drugs | OTC & Nutraceuticals | $178 Bn | 4.7% |
| Over The Counter (OTC) Pharmaceuticals | OTC & Nutraceuticals | $178 Bn | 4.7% |
| Over The Counter (OTC) Analgesics | OTC & Nutraceuticals | $22 Bn | 3.4% |
| Over The Counter (OTC) Gastrointestinal Drugs | OTC & Nutraceuticals | $5.6 Bn | 3.9% |
| Iron Supplement | OTC & Nutraceuticals | $2 Bn | 6.5% |
| Antipyretics OTC | OTC & Nutraceuticals | – | – |
Named as key players in the same markets as Reckitt Benckiser Group PLC (number of shared markets).
Johnson & Johnson5 shared markets
Bayer AG4 shared markets
GSK PLC4 shared markets
Novartis AG3 shared markets
Pfizer Inc.3 shared markets
AstraZeneca2 shared markets
Boehringer Ingelheim International GmbH2 shared markets
Dr Reddy’s Laboratories2 shared markets
Search all reports for Reckitt Benckiser Group PLC All companies